Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (71-80 of 401) with videos related to

Pageof 41
Sort By:
Thrombosis and Haemostasis|September 28, 2002
Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirinRobert F Storey, Heather M Judge, Robert G Wilcox, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 19, 2016
Population pharmacokinetics of ticagrelor in patients with acute coronary syndromesJianguo Li, Weifeng Tang, Robert F Storey, et al.
Thrombosis and Haemostasis|May 30, 2006
Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary interventionAnjan Siotia, Robert Buckland, Heather M Judge, et al.
Platelets|April 13, 2005
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromesMiles W H Behan, Susan C Fox, Stan Heptinstall, et al.
Thrombosis and Haemostasis|August 21, 2019
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-AnalysesKarsten Schrör, Steen D Kristensen, Robert F Storey, et al.
Platelets|August 14, 2015
Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitroHeather M Judge, Robert J Buckland, Joseph A Jakubowski, et al.
Platelets|December 16, 2022
Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuumFrances L Varian, William A E Parker, James Fotheringham, et al.
Platelets|March 15, 2005
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary interventionSimon M G Smith, Heather M Judge, Gary Peters, et al.
Platelets|October 21, 2005
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responsesHeather M Judge, Robert J Buckland, Carol E Holgate, et al.
Expert Opinion on Pharmacotherapy|January 4, 2025
Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?Mohammed Ejaz Faizur Rahman, Vidun Wedagedera, William A E Parker, et al.
Pageof 41

Showing results (71-80 of 401) with videos related to

Sort By:
Pageof 41
Thrombosis and Haemostasis|September 28, 2002
Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirinRobert F Storey, Heather M Judge, Robert G Wilcox, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 19, 2016
Population pharmacokinetics of ticagrelor in patients with acute coronary syndromesJianguo Li, Weifeng Tang, Robert F Storey, et al.
Thrombosis and Haemostasis|May 30, 2006
Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary interventionAnjan Siotia, Robert Buckland, Heather M Judge, et al.
Platelets|April 13, 2005
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromesMiles W H Behan, Susan C Fox, Stan Heptinstall, et al.
Thrombosis and Haemostasis|August 21, 2019
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-AnalysesKarsten Schrör, Steen D Kristensen, Robert F Storey, et al.
Platelets|August 14, 2015
Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitroHeather M Judge, Robert J Buckland, Joseph A Jakubowski, et al.
Platelets|December 16, 2022
Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuumFrances L Varian, William A E Parker, James Fotheringham, et al.
Platelets|March 15, 2005
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary interventionSimon M G Smith, Heather M Judge, Gary Peters, et al.
Platelets|October 21, 2005
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responsesHeather M Judge, Robert J Buckland, Carol E Holgate, et al.
Expert Opinion on Pharmacotherapy|January 4, 2025
Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?Mohammed Ejaz Faizur Rahman, Vidun Wedagedera, William A E Parker, et al.
Pageof 41